Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03451435 · ClinicalTrials.gov registry record · Early Phase 1
N-Acetyl Cysteine Protects Pulpal Stem Cells in Endodontic Revascularization
A Early Phase 1 study, sponsored by University of California, Los Angeles.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 7
- Enrollment target
NCT03451435: Clinical Trial Early Phase 1 study, sponsored by University of California, Los Angeles.
NCT03451435 is a Early Phase 1 study that was terminated before completion, run by University of California, Los Angeles. The registered enrollment target is 7 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03451435, a Early Phase 1 study, was terminated before completion, sponsored by University of California, Los Angeles.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
Pulp re-vascularization/regeneration is a procedure performed to allow pulpal stem cells to survive and/or differentiate to allow immature tooth root structures to grow to full maturity. Currently, the procedure includes disinfection of the necrotic root canal space and induction of bleeding to potentiate pulpal stem cell differentiation to allow root growth on an immature root. A number of studies conducted previously demonstrate that N-acetyl cysteine (NAC) potentiates differentiation of pulpal stem/stromal cells and protects pulpal cells from apoptosis. 14-18 human subjects will be recruited forming two groups where pulp re-vascularization/regeneration procedures will be performed with or without the use of NAC treatment prior to induction of bleeding. Recall follow-up appointments will be done at 6 months and 1 year post treatment with subsequent yearly appointments until full root growth has been achieved.
Primary Outcome
Change of root length in millimeters over time
Interventions
- DRUG N acetyl cysteine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2018-06-15 |
| Est. Completion | 2019-04-01 |
| Phase | Early Phase 1 |
Why NCT03451435 stopped before completion
NCT03451435 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 1 intervention - of which N acetyl cysteine is the first listed.
NCT03451435 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03451435 about?
NCT03451435 is a clinical study titled "N-Acetyl Cysteine Protects Pulpal Stem Cells in Endodontic Revascularization". Pulp re-vascularization/regeneration is a procedure performed to allow pulpal stem cells to survive and/or differentiate to allow immature tooth root structures to grow to full maturity. Currently, the procedure includes disinfection of the necrotic root canal space and induction of bleeding to pote...
What is the current status of trial NCT03451435?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 7 participants. The study started on 2018-06-15. Estimated completion is 2019-04-01.
What interventions are being tested in trial NCT03451435?
The interventions under investigation include: N acetyl cysteine (DRUG).
Who is sponsoring clinical trial NCT03451435?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03451435's enrollment target sits among peer trials
7 1825th of 2000 higher than 156 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI